Table 2.
Cancer stage and performance status
| Trial | Cancer type | Stage of Cancer | ECOG 0 or 1 in statin group | ECOG 0 or 1 in control group | ECOG 2 or 3 in statin group | ECOG 2 or 3 in control group | |
|---|---|---|---|---|---|---|---|
| Statin group | Control group | ||||||
| Alexandre et al. [21] | Oesophageal/GOJ adenocarcinoma | Up to stage 3 | 93.8% | 100% | 6.2% | 0% | |
| Jouve et al. [22] | Hepatocellular Carcinoma |
Child-Pugh A Extra-hepatic Metastatic disease: 29.0% |
Child-Pugh A Extra-hepatic metastatic disease: 30.4% |
95.7% | 95% | 4.3% | 5% |
| Lee et al. [23] | Non-adenocarcinomatous Non-small cell lung cancer | Stage 3B/4b | 75% | 75% | 25% | 25% | |
| Seckl et al. [24] | Small cell lung cancer | Limited diseasec: 43.4% | Limited diseasec: 42.7%, | 75.6% | 75.2% | 24.4% | 24.8% |
| Extensive diseasec: 56.6% | Extensive diseasec: 49.5% | ||||||
| El-Hamamsy et al. [25] | Brain metastases (various primariesa) | Stage 4 | NSe | NS | NS | NS | |
| Lim et al. [26] | Colorectal Cancer | Stage 4b | 98.5% | 98.5% | 1.5%g | 1.5%g | |
| Kim et al. [27] | Gastric/GOJ adenocarcinoma | Stage 4b | 99.2% | 96.7% | 0.8% | 3.3% | |
| Hong et al. [28] | Pancreatic cancer | Locally advanced disease: 12% | Locally advanced disease: 12.5% | 100% | 100% | 0% | 0% |
| Metastatic disease: 88% | Metastatic disease: 87.5% | ||||||
| Han et al. [29] | Non-small cell lung cancer | Stage 3bb: 6%, stage 4: 94% | Stage 3bb: 11%, stage 4: 89% | 94% | 89% | 6% | 11% |
| Konings et al. [30] | Gastric adenocarcinoma | ≥ 43% metastatic disease | 86.7% | 100% | 13.3%g | 0% | |
| Kawata et al. [31] | Hepatocellular carcinoma | Stage 2–3d: 73%, stage 4: 27% | Stage 2–3d: 69%, stage 4: 31% | NSf | NS | NS | NS |
ECOG Eastern Cooperative Oncology Group, GOJ gastro-oesophageal, NS not stated
aPrimary cancers were mostly breast and lung cancers (in 88% of patients)
bAmerican Joint Committee on Cancer TNM staging
cVeterans Administration Lung Study Group Staging
dPrimary Liver Cancer Study Group of Japan staging
e36% in the statin group and 28% in the control group had a Karnofsky performance scale score of > = 70%
f83% in the statin group and 86% in the control group had a Karnofsky performance scale score of > 70%
gNo ECOG > 2 patients
f83% in the statin group and 86% in the control group had a Karnofsky performance scale score of > 70%